Live Breaking News & Updates on Cell Amp Gene Therapies|Page 4

Stay updated with breaking news from Cell amp gene therapies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Positive pre-IND meeting with FDA for new ovarian cancer cell therapy

Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has completed a pre-investigational new drug (pre-IND) meeting with the FDA for a phase 1/2 clinical trial of its cell therapy product, CTH-401 for the treatment of ovarian cancer. ....

Alan Trounson , Investigational New Drug , Bio Developments , Markets Amp Regulations , Cell Amp Gene Therapies , Ovarian Cancer , Cell And Gene Therapy , Cell Therapy ,

GDMC secures $21 million to expand advanced genetic therapies

Genetic Design and Manufacturing Corporation (GDMC) has bagged $21 million in Series A funding to accelerate its next-gen advanced genetic therapies. ....

Donald Tang , Michael Koeris , Jonathan Su , Wi Harper Group , Celadon Partners , Tan Kaixin , Markets Amp Regulations , Bio Developments , Emerging Markets , Cell Amp Gene Therapies , Advanced Therapies , Gene Therapy , Supply Chain ,

ReciBioPharm: Enhancing gene therapies through flexibile AAV platforms

We sat down with Xiaojun Liu, director of AAV process development at ReciBioPharm, to discuss the growing need for carefully designed platforms to deliver safe and cost-effective AAV therapies to patients at pace. ....

Bio Developments , Emerging Markets , Cell Amp Gene Therapies , Cell And Gene Therapy , Cell Therapy , Gene Therapy , Aav Platform ,

4basebio: Unlocking the potential of synthetic DNA

We took the time to speak with Amy Walker, vice president at 4basebio, to discuss the merits of synthetic DNA and its future application. ....

Bio Developments , Emerging Markets , Cell Amp Gene Therapies , Ynthetic Dna Vector , Gene Editing , Gene Therapy ,

ReciBioPharm: Enhancing gene therapies through flexible AAV platforms

We sat down with Xiaojun Liu, director of AAV process development at ReciBioPharm, to discuss the growing need for carefully designed platforms to deliver safe and cost-effective AAV therapies to patients at pace. ....

Bio Developments , Emerging Markets , Cell Amp Gene Therapies , Cell And Gene Therapy , Cell Therapy , Gene Therapy , Aav Platform ,